Companies Outset Medical, Inc.
Outset Medical (OM): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Outset Medical, Inc.’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers24th pct.Of 17 peer CEOs
CEO pay, last three years
- $6,474,946FY2023
- $4,002,620FY2024
- $3,255,510FY2025
CEO total pay was $3,255,510 in fiscal 2025, down from $4,002,620 in fiscal 2024.
FY2025: salary $755,166 · bonus $0 · stock awards $2,197,882 · option awards $0
Executives and directors
Renee Gaeta · CFOLeslie Trigg · CEOMarc Nash · EVPNabeel Ahmed · CFOJohn Brottem · General CounselAndrea L. Saia · Former director (through FY2025)Brent D. Lang · Independent DirectorD. Keith Grossman · Lead Independent DirectorDale E. Jones · Former director (through FY2025)Karen Drexler · Independent DirectorKaren Prange · Independent DirectorKevin O'Boyle · Independent DirectorPatrick T. Hackett · Independent Director
Frequently asked questions
Who was the highest-paid executive at Outset Medical, Inc. in fiscal 2025?
As disclosed, Renee Gaeta (Chief Financial Officer) was the highest-paid executive at Outset Medical, Inc. in fiscal 2025, with total compensation of $3,398,025.
How does Outset Medical, Inc.'s chief executive pay compare to its disclosed peer group?
As disclosed, Leslie Trigg's total compensation ranked at the 24th percentile of Outset Medical, Inc.'s disclosed peer group.
What is Outset Medical, Inc.'s CEO-to-median employee pay ratio?
As disclosed, Outset Medical, Inc.'s CEO-to-median employee pay ratio was 24:1.
How did shareholders vote on Outset Medical, Inc.'s executive compensation?
As disclosed, 70.25% of shareholders supported Outset Medical, Inc.'s executive compensation in the latest say-on-pay vote.
How much does Outset Medical, Inc. spend in total on board compensation for fiscal 2025?
As disclosed, Outset Medical, Inc. reported total board compensation of $1,654,920 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Renee Gaeta | $276,923 | $0 | $3,061,977 | $0 | $54,000 | $0 | $5,125 | $3,398,025 |
| Chief Financial Officer | ||||||||
| Leslie Trigg | 755,166 | 0 | 2,197,882 | 0 | 294,515 | 0 | 7,947 | 3,255,510 |
| President, CEO and Chair of the Board | ||||||||
| John Brottem | 466,595 | 1,000 | 838,557 | 0 | 90,986 | 0 | 7,506 | 1,404,644 |
| General Counsel and Secretary | ||||||||
| Marc Nash | 432,577 | 0 | 783,340 | 0 | 84,353 | 0 | 7,198 | 1,307,468 |
| Executive Vice President, R&D, Operations and Service | ||||||||
| Nabeel Ahmed | 212,841 | 0 | 0 | 0 | 0 | 0 | 397,287 | 610,128 |
| Former Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Renee Gaeta | $3,398,025 | — | — | — |
| Leslie Trigg | 3,255,510 | 4,002,620 | 6,474,946 | ↓ −747,110 |
| John Brottem | 1,404,644 | 1,510,518 | 1,744,514 | ↓ −105,874 |
| Marc Nash | 1,307,468 | — | — | — |
| Nabeel Ahmed | 610,128 | 1,791,014 | 2,328,951 | ↓ −1,180,886 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
Our executive compensation program is designed to meet the following key objectives: Attract, mobilize and retain the right talent. Executive compensation should be market-competitive in order to attract and retain highly qualified, experienced and motivated talent to act as inspirational leaders, drive our strategic initiatives, grow our business and help pave the way to a patient-centric dialysis service model. Incentivize a collective focus on corporate goals. Our work environment is goal-driven and we believe compensation is a critical tool in the successful execution of our business objectives. By tying elements of our executives pay to key corporate goals, we encourage our executives to focus their teams and execute on these goals. Reward and recognize outstanding performance. We firmly believe that executive compensation should incentivize and reward outstanding performance that contributes to our overall growth and success as a company both in the short term and long term. Create long-term stockholder value. Through the risks and rewards of owning Outset equity, we incentivize our executives to stay focused collectively on activities that intended to ensure Outset s sustainable success.
| CEO STI target (% of salary) | 100% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Pearl Meyer |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| John Brottem | PSU | 2025-06-10 | 1,349 | 2,699 | — | 5,398 | $95,302 |
| John Brottem | RSU | 2025-06-10 | — | — | 35,993 | — | 743,255 |
| Leslie Trigg | RSU | 2025-06-10 | — | — | 65,103 | — | 1,344,377 |
| Renee Gaeta | PSU | 2025-06-10 | 4,928 | 9,857 | — | 19,714 | 348,051 |
| Renee Gaeta | RSU | 2025-06-10 | — | — | 131,425 | — | 2,713,926 |
| Marc Nash | PSU | 2025-06-10 | 1,113 | 2,226 | — | 4,452 | 78,600 |
| Marc Nash | RSU | 2025-06-10 | — | — | 29,676 | — | 612,809 |
| Marc Nash | RSU | 2025-08-25 | — | — | 5,617 | — | 77,065 |
| Leslie Trigg | PSU | 2025-06-10 | 9,765 | 19,531 | — | 48,827 | 853,505 |
| Marc Nash | PSU | 2025-08-25 | 210 | 421 | — | 842 | 14,866 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| John Brottem | $743,255 | $95,302 | $0 | 11.4% |
| Leslie Trigg | 1,344,377 | 853,505 | 0 | 38.8% |
| Renee Gaeta | 2,713,926 | 348,051 | 0 | 11.4% |
| Marc Nash | 689,874 | 93,466 | 0 | 11.9% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Marc Nash | RSU | 107 | — | $397 |
| Marc Nash | PSU | 210 | — | 779 |
| John Brottem | PSU | 240 | — | 890 |
| Marc Nash | PSU | 240 | — | 890 |
| Marc Nash | PSU | 1,113 | — | 4,129 |
| John Brottem | PSU | 1,349 | — | 5,005 |
| John Brottem | PSU | 1,666 | — | 6,181 |
| Marc Nash | PSU | 1,666 | — | 6,181 |
| Leslie Trigg | PSU | 1,942 | — | 7,205 |
| Leslie Trigg | PSU | 2,125 | — | 7,884 |
| John Brottem | RSU | 2,135 | — | 7,921 |
| Marc Nash | RSU | 2,135 | — | 7,921 |
| Leslie Trigg | PSU | 3,333 | — | 12,365 |
| Leslie Trigg | RSU | 4,724 | — | 17,526 |
| Renee Gaeta | PSU | 4,928 | — | 18,283 |
| Marc Nash | RSU | 5,617 | — | 20,839 |
| Marc Nash | RSU | 8,609 | — | 31,939 |
| John Brottem | RSU | 9,061 | — | 33,617 |
| Nabeel Ahmed | RSU | 9,315 | — | 34,559 |
| Leslie Trigg | PSU | 9,765 | — | 36,228 |
| Leslie Trigg | RSU | 24,177 | — | 89,697 |
| Marc Nash | RSU | 29,676 | — | 110,098 |
| John Brottem | RSU | 35,993 | — | 133,534 |
| Leslie Trigg | RSU | 65,103 | — | 241,532 |
| Renee Gaeta | RSU | 131,425 | — | 487,587 |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Kevin O'BoyleIndependent · Newly elected | $40,893 | $439,985 | $0 | $0 | $0 | $480,878 |
| D. Keith GrossmanIndependent · Lead Independent Director · Compensation (Chair) · Nominating and Corporate Governance | 111,291 | 159,987 | 0 | 0 | 0 | 271,278 |
| Karen DrexlerIndependent · Compensation · Nominating and Corporate Governance (Chair) | 65,000 | 159,987 | 0 | 0 | 0 | 224,987 |
| Patrick T. HackettIndependent · Audit · Nominating and Corporate Governance | 63,709 | 159,987 | 0 | 0 | 0 | 223,696 |
| Andrea L. SaiaIndependent · Audit · Compensation · Departed during FY | 55,000 | 159,987 | 0 | 0 | 0 | 214,987 |
| Brent D. LangIndependent · Audit | 55,000 | 159,987 | 0 | 0 | 0 | 214,987 |
| Dale E. JonesIndependent · Compensation (Chair) · Departed during FY | 24,107 | — | 0 | 0 | 0 | 24,107 |
| Karen PrangeIndependent · Compensation · Newly elected | 0 | 0 | 0 | 0 | 0 | 0 |
| Leslie TriggEmployee director · Board Chair | 0 | 0 | 0 | — | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $45,000 |
|---|---|
| Annual equity retainer | $160,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 20,000 / 10,000 |
| Stock ownership guideline | 3x annual cash retainer |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $415,000 |
| Equity awards (grant-date value) | $1,239,920 |
| All other compensation | $0 |
| Total cost of the board | $1,654,920 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Outset Medical as a peer
Companies that benchmark against OM
2 companies name OM as a compensation peer
- MIMEDX GROUP, INC.MDXGFY2025
- TACTILE SYSTEMS TECHNOLOGY INCTCMDFY2025
Each company listed discloses OM in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named OM in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
PACB Pacific Biosciences of California, Inc.PRCT PROCEPT BioRobotics CorporationLUNG Pulmonx CorporationARAY Accuray IncorporatedADPT Adaptive Biotechnologies CorporationANGO AngioDynamics, Inc.BFLY Butterfly Network, Inc.CDNA CareDx, Inc.INGN Inogen, Inc.STIM Neuronetics, Inc.NPCE NeuroPace, Inc.SIBN SI-BONE, Inc.SGHT Sight Sciences, Inc.TCMD Tactile Systems Technology, Inc.TMCI Treace Medical Concepts, Inc.NVRO Nevro Corp.FNA Paragon 28, Inc.
Peer reciprocity
The companies Outset Medical, Inc. names as compensation peers that name it back in their own disclosed peer groups.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Procept BioRobotics Corporation | 2025 | Larry Wood | $304,830 | $7,217,251 | $7,226,599 | $243,864 | $16,783,853 |
| 2 | Nevro Corp. | 2023 | Kevin Thornal | 515,625 | 10,080,173 | 0 | 402,750 | 11,453,548 |
| 3 | Adaptive Biotechnologies Corporation | 2025 | Chad Robins | 698,258 | 7,675,100 | 0 | 703,380 | 9,081,690 |
| 4 | SI-Bone, Inc. | 2025 | Laura Francis | 685,000 | 6,038,710 | 0 | 729,525 | 7,453,235 |
| 5 | CareDx, Inc. | 2025 | John Hanna | 693,269 | 5,622,638 | 0 | 852,515 | 7,179,699 |
| 6 | Butterfly Network, Inc. | 2025 | Joseph DeVivo | 900,300 | 4,291,604 | 0 | 1,183,000 | 6,382,814 |
| 7 | AngioDynamics, Inc. | 2026 | James Clemmer | 828,171 | 3,689,866 | 0 | 1,502,491 | 6,060,145 |
| 8 | Treace Medical Concepts, Inc. | 2025 | John Treace | 755,353 | 4,635,000 | 0 | 0 | 5,405,190 |
| 9 | Accuray Incorporated | 2026 | Steve La Neve | 525,000 | 4,263,749 | 0 | 0 | 5,114,466 |
| 10 | Neuronetics, Inc. | 2025 | Keith Sullivan | 728,000 | 3,208,750 | 0 | 412,776 | 4,365,064 |
| 11 | Pacific Biosciences of California, Inc. | 2025 | Christian Henry | 748,250 | 1,151,013 | 1,696,278 | 714,305 | 4,309,846 |
| 12 | Pulmonx Corporation | 2025 | Glendon French | 116,186 | 3,224,000 | 0 | 0 | 3,543,520 |
| 13 | Tactile Systems Technology, Inc. | 2025 | Sheri Dodd | 675,000 | 2,019,978 | 0 | 737,438 | 3,466,916 |
| 14 | Outset Medical, Inc. | 2025 | Leslie Trigg | 755,166 | 2,197,882 | 0 | 294,515 | 3,255,510 |
| 15 | Paragon 28, Inc. | 2023 | Albert DaCosta | 700,769 | 1,832,495 | 0 | 667,400 | 3,232,420 |
| 16 | Inogen, Inc. | 2025 | Kevin R.M. Smith | 711,077 | 1,874,550 | 0 | 0 | 2,613,804 |
| 17 | NeuroPace, Inc. | 2025 | Joel Becker | 567,567 | 587,340 | 701,850 | 551,810 | 2,408,566 |
| 18 | Sight Sciences, Inc. | 2025 | Paul Badawi | 659,000 | 1,000,000 | 0 | 334,607 | 2,005,608 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Outset Medical, Inc. | 39% | PSU 50 · RSU 50 | Yes — Relative TSR compared to Russell 2000 Medical Device Index | Pearl Meyer |
| Accuray Incorporated | 0% | PSU 50 · RSU 50 | No | Exequity LLP |
| Adaptive Biotechnologies Corporation | not disclosed | RSU 50 · PSU 50 | not disclosed | Semler Brossy Consulting Group, LLC |
| AngioDynamics, Inc. | 180% | PSU 50 · RSU 50 | No | Meridian Compensation Partners, LLC |
| Butterfly Network, Inc. | 131.25% for Joseph DeVivo; 109.2% for Steven Cashman% | not disclosed | No | Pay Governance |
| CareDx, Inc. | not disclosed | RSU 70 · PRSU 30 | No | Alpine Rewards |
| Inogen, Inc. | 60% | RSU 50 · PRSU 50 | No | Aon |
| Neuronetics, Inc. | not disclosed | not disclosed | not disclosed | Alpine Rewards, LLC |
| NeuroPace, Inc. | not disclosed | not disclosed | not disclosed | Alpine, Inc. |
| Nevro Corp. | 53.7% | not disclosed | No | Aon |
| Pacific Biosciences of California, Inc. | 95% | not disclosed | not disclosed | Aon Human Capital Solutions |
| Paragon 28, Inc. | 94% | RSU 100 | not disclosed | Compensia, Inc. |
| Procept BioRobotics Corporation | 80% | RSU 50 · PSU 25 · Options 25 | Yes — Relative TSR | Alpine |
| Pulmonx Corporation | not disclosed | RSU 75 · PRSU 25 | not disclosed | Frederic W. Cook & Co., Inc. |
| SI-Bone, Inc. | 106.5% | RSU 50 · PSU 50 | Yes — Relative TSR | Compensia, Inc. |
| Sight Sciences, Inc. | not disclosed | RSU 100 | not disclosed | Compensia, Inc. |
| Tactile Systems Technology, Inc. | 115% | PSU 50 · RSU 50 | No | Aon Consulting, Inc. |
| Treace Medical Concepts, Inc. | not disclosed | RSU 50 · PSU 50 | No | Compensia, Inc. |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-04 | 7,548,774 | 3,196,870 | 6,411 | 70.25% | Passed |
| 2025 | 2025-06-02 | 13,574,133 | 342,501 | 5,839 | 97.54% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-04 | 70.25%a |
| 2025 | 2025-06-02 | 97.54%b |
a. Approved under the standard stated in the filing — “Abstentions are not considered "votes cast" and therefore will not affect the outcome of this proposal.”.
b. Approved under the standard stated in the filing — “Abstentions are not considered "votes cast" and therefore will not affect the outcome of this proposal.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 24 : 1 |
|---|---|
| CEO total compensation | $3,255,510 |
| Median employee compensation | $135,629 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Braden Michael Leonard | Greater-than-10% holder | 2026-05-08 | A | 197,600 | $5 | $988,000 | Common, indirect | Form 4 ↗ |
| Braden Michael Leonard | Greater-than-10% holder | 2026-05-11 | A | 96,900 | 5 | 484,500 | Common, indirect | Form 4 ↗ |
| John Brottem | General Counsel | 2026-05-15 | D | 2,638 | 4 | 9,761 | Common | Form 4 ↗ |
| Marc Nash | EVP Operations R&D & Service | 2026-05-15 | D | 1,582 | 4 | 5,853 | Common | Form 4 ↗ |
| Leslie Trigg | Director | 2026-05-15 | D | 3,445 | 4 | 12,747 | Common | Form 4 ↗ |
| Braden Michael Leonard | Greater-than-10% holder | 2026-05-15 | A | 323,000 | 5 | 1,615,000 | Common, indirect | Form 4 ↗ |
| Renee Gaeta | Chief Financial Officer | 2026-06-03 | D | 17,672 | 5 | 87,300 | Common | Form 4 ↗ |
| Karen Drexler | Director | 2026-06-04 | A | 10,667 | 0 | 0 | RSU | Form 4 ↗ |
| D. Keith Grossman | Director | 2026-06-04 | A | 10,667 | 0 | 0 | RSU | Form 4 ↗ |
| Karen Prange | Director | 2026-06-04 | A | 10,667 | 0 | 0 | RSU | Form 4 ↗ |
| Kevin C. Oboyle | Director | 2026-06-04 | A | 10,667 | 0 | 0 | RSU | Form 4 ↗ |
| Patrick T. Hackett | Director | 2026-06-04 | A | 10,667 | 0 | 0 | RSU | Form 4 ↗ |
| Brent D. Lang | Director | 2026-06-04 | A | 10,667 | 0 | 0 | RSU | Form 4 ↗ |
| Renee Gaeta | Chief Financial Officer | 2026-06-26 | A | 71,630 | 0 | 0 | Common | Form 4 ↗ |
| John Brottem | General Counsel | 2026-06-26 | A | 59,830 | 0 | 0 | Common | Form 4 ↗ |
| Leslie Trigg | Director | 2026-06-26 | A | 99,160 | 0 | 0 | Common | Form 4 ↗ |
| Leslie Trigg | Director | 2026-08-17 | D | 3,437 | 4 | 15,088 | Common | Form 4 ↗ |
| Renee Gaeta | Chief Financial Officer | 2026-08-17 | D | 4,543 | 4 | 19,944 | Common | Form 4 ↗ |
| John Brottem | General Counsel | 2026-08-17 | D | 2,632 | 4 | 11,554 | Common | Form 4 ↗ |
| Braden Michael Leonard | Greater-than-10% holder | 2026-10-01 | A | 228,334 | 4 | 806,019 | Common, indirect | Form 4 ↗ |
| Braden Michael Leonard | Greater-than-10% holder | 2026-10-02 | A | 16,575 | 4 | 64,241 | Common, indirect | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (70 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Renee Gaeta. DEF 14A, filed 2026-04-24. Section “2025 Summary Compensation Table”. As printed: 3,398,025. View filing ↗
- Section 01, Leslie Trigg. DEF 14A, filed 2026-04-24. Section “2025 Summary Compensation Table” · page 51. As printed: 3,255,510. View filing ↗
- Section 01, John Brottem. DEF 14A, filed 2026-04-24. Section “2025 Summary Compensation Table”. As printed: 1,404,644. View filing ↗
- Section 01, Marc Nash. DEF 14A, filed 2026-04-24. Section “2025 Summary Compensation Table”. As printed: 1,307,468. View filing ↗
- Section 01, Nabeel Ahmed. DEF 14A, filed 2026-04-24. Section “2025 Summary Compensation Table”. As printed: 610,128. View filing ↗
- Section 03, John Brottem PSU. DEF 14A, filed 2026-04-24. Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. View filing ↗
- Section 03, John Brottem RSU. DEF 14A, filed 2026-04-24. Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Leslie Trigg RSU. DEF 14A, filed 2026-04-24. Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Renee Gaeta PSU. DEF 14A, filed 2026-04-24. Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Renee Gaeta RSU. DEF 14A, filed 2026-04-24. Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Marc Nash PSU. DEF 14A, filed 2026-04-24. Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Marc Nash RSU. DEF 14A, filed 2026-04-24. Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Marc Nash RSU. DEF 14A, filed 2026-04-24. Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Leslie Trigg PSU. DEF 14A, filed 2026-04-24. Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Marc Nash PSU. DEF 14A, filed 2026-04-24. Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2026-04-24. Section “CEO Pay Ratio”. As printed: 24 : 1. View filing ↗
- Section 08, Kevin O'Boyle. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 480,878. View filing ↗
- Section 08, D. Keith Grossman. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 271,278. View filing ↗
- Section 08, Karen Drexler. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 224,987. View filing ↗
- Section 08, Patrick T. Hackett. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 223,696. View filing ↗
- Section 08, Andrea L. Saia. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 214,987. View filing ↗
- Section 08, Brent D. Lang. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 214,987. View filing ↗
- Section 08, Dale E. Jones. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 24,107. View filing ↗
- Section 08, Karen Prange. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Leslie Trigg. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Braden Michael Leonard 2026-05-08. Form 4, filed 2026-05-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Braden Michael Leonard 2026-05-11. Form 4, filed 2026-05-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Brottem 2026-05-15. Form 4, filed 2026-05-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Marc Nash 2026-05-15. Form 4, filed 2026-05-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Leslie Trigg 2026-05-15. Form 4, filed 2026-05-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Braden Michael Leonard 2026-05-15. Form 4, filed 2026-05-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Renee Gaeta 2026-06-03. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Karen Drexler 2026-06-04. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, D. Keith Grossman 2026-06-04. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Karen Prange 2026-06-04. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin C. Oboyle 2026-06-04. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Patrick T. Hackett 2026-06-04. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brent D. Lang 2026-06-04. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Renee Gaeta 2026-06-26. Form 4, filed 2026-06-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Brottem 2026-06-26. Form 4, filed 2026-06-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Leslie Trigg 2026-06-26. Form 4, filed 2026-06-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Leslie Trigg 2026-08-17. Form 4, filed 2026-08-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Renee Gaeta 2026-08-17. Form 4, filed 2026-08-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Brottem 2026-08-17. Form 4, filed 2026-08-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Braden Michael Leonard 2026-10-01. Form 4, filed 2026-10-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Braden Michael Leonard 2026-10-02. Form 4, filed 2026-10-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-05. Item 5.07 · say-on-pay result. As reported: 70.25% (votes for as printed: 7,548,774). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-06-03. Item 5.07 · say-on-pay result. As reported: 97.54% (votes for as printed: 13,574,133). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 415,000 + equity 1,239,920 + all other 0 = 1,654,920, summed across the director compensation table rows.
- Procept BioRobotics Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Procept BioRobotics Corporation's own proxy. As printed: 16,783,853. View filing ↗
- Nevro Corp., Section 10b CEO total. DEF 14A, filed 2024-04-12. CEO total compensation as printed in Nevro Corp.'s own proxy. As printed: 11,453,548. View filing ↗
- Adaptive Biotechnologies Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Adaptive Biotechnologies Corporation's own proxy. As printed: 9,081,690. View filing ↗
- SI-Bone, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in SI-Bone, Inc.'s own proxy. As printed: 7,453,235. View filing ↗
- CareDx, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in CareDx, Inc.'s own proxy. As printed: 7,179,699. View filing ↗
- Butterfly Network, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in Butterfly Network, Inc.'s own proxy. As printed: 6,382,814. View filing ↗
- AngioDynamics, Inc., Section 10b CEO total. DEF 14A, filed 2026-10-08. CEO total compensation as printed in AngioDynamics, Inc.'s own proxy. As printed: 6,060,145. View filing ↗
- Treace Medical Concepts, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in Treace Medical Concepts, Inc.'s own proxy. As printed: 5,405,190. View filing ↗
- Accuray Incorporated, Section 10b CEO total. DEF 14A, filed 2026-10-16. CEO total compensation as printed in Accuray Incorporated's own proxy. As printed: 5,114,466. View filing ↗
- Neuronetics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-09. CEO total compensation as printed in Neuronetics, Inc.'s own proxy. As printed: 4,365,064. View filing ↗
- Pacific Biosciences of California, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Pacific Biosciences of California, Inc.'s own proxy. As printed: 4,309,846. View filing ↗
- Pulmonx Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Pulmonx Corporation's own proxy. As printed: 3,543,520. View filing ↗
- Tactile Systems Technology, Inc., Section 10b CEO total. DEF 14A, filed 2026-03-25. CEO total compensation as printed in Tactile Systems Technology, Inc.'s own proxy. As printed: 3,466,916. View filing ↗
- Outset Medical, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Outset Medical, Inc.'s own proxy. As printed: 3,255,510. View filing ↗
- Paragon 28, Inc., Section 10b CEO total. DEF 14A, filed 2024-04-05. CEO total compensation as printed in Paragon 28, Inc.'s own proxy. As printed: 3,232,420. View filing ↗
- Inogen, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Inogen, Inc.'s own proxy. As printed: 2,613,804. View filing ↗
- NeuroPace, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in NeuroPace, Inc.'s own proxy. As printed: 2,408,566. View filing ↗
- Sight Sciences, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Sight Sciences, Inc.'s own proxy. As printed: 2,005,608. View filing ↗
- Section 10a, Tactile Systems Technology, Inc. reciprocity. DEF 14A. Tactile Systems Technology, Inc. names Outset Medical, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗